Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS

被引:34
作者
Lalezari, S. [1 ]
Martinowitz, U. [1 ]
Windyga, J. [2 ]
Enriquez, M. M. [3 ]
Delesen, H. [3 ]
Schwartz, L. [4 ]
Scharrer, I. [5 ]
机构
[1] Chaim Sheba Med Ctr, Natl Hemophilia Ctr, IL-52621 Tel Hashomer, Israel
[2] Inst Hematol & Transfus Med, Warsaw, Poland
[3] Bayer Pharma AG, Wuppertal, Germany
[4] Bayer HealthCare Pharmaceut Inc, Montville, NJ USA
[5] Univ Hosp, Mainz, Germany
关键词
age; factor VIII; pharmacokinetics; von Willebrand factor; VON-WILLEBRAND-FACTOR; QUALITY-OF-LIFE; BLOOD-GROUP-O; FACTOR-VIII; HALF-LIFE; RECOMBINANT; INCREASES; SHORTER;
D O I
10.1111/hae.12294
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with severe haemophilia A experience frequent and spontaneous bleeding, causing debilitating damage to joints and decreasing quality of life. Prophylaxis with factor VIII (FVIII) reduces joint damage if initiated early. Circulating FVIII levels may be influenced by endogenous von Willebrand factor (VWF), a chaperone protein that binds and stabilizes FVIII. The aim of this study was to determine whether endogenous VWF antigen (VWF:Ag) levels are correlated with FVIII pharmacokinetic (PK) parameters and clinical outcomes in patients with severe haemophilia A. Previously treated, non-inhibitor patients in a multinational, randomized, double-blind, Ph II study received prophylaxis with once-weekly BAY 79-4980 (35IUkg(-1)) or thrice-weekly recombinant sucrose-formulated FVIII (rFVIII-FS; 25IUkg(-1)). PK parameters were evaluated at weeks 1 and 26. The number of bleeds per patient during the study was captured as part of the core efficacy endpoint. Spearman rank correlations assessed relationships of VWF:Ag levels with patient age, PK and annualized bleeding rate. Of 131 study patients (aged 13-64years; BAY 79-4980, n=63; rFVIII-FS, n=68), 27 (21%; n=15 and 12 respectively) were evaluable for PK assessment. Baseline VWF:Ag levels correlated with patient age (P<0.0001). There was no significant difference in PK results between treatments; thus, PK parameters and VWF levels of all patients were analysed together. AUC(norm) and T-1/2 significantly increased with increased VWF:Ag (P<0.001); clearance significantly decreased with increased VWF:Ag (P=0.002). Annualized bleeding rate in patients treated with 3x per week rFVIII-FS significantly correlated with VWF:Ag and age (P=0.038 and 0.021 respectively). PK parameters as well as the clinical outcome significantly correlated with endogenous VWF:Ag. The improved clinical outcome in subjects with high VWF:Ag levels may be explained by VWF:Ag influence on FVIII PK.
引用
收藏
页码:E15 / E22
页数:8
相关论文
共 27 条
[11]   Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients [J].
Fischer, Kathelijn ;
Pendu, Ronan ;
van Schooten, Carina J. ;
van Dijk, Karin ;
Denis, Cecile V. ;
van den Berg, H. Marijke ;
Lenting, Peter J. .
PLOS ONE, 2009, 4 (08)
[12]   A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor [J].
Gallinaro, Lisa ;
Cattini, Maria Grazia ;
Sztukowska, Maryta ;
Padrini, Roberto ;
Sartorello, Francesca ;
Pontara, Elena ;
Bertornoro, Antonella ;
Daidone, Viviana ;
Pagnan, Antonio ;
Casonato, Alessandra .
BLOOD, 2008, 111 (07) :3540-3545
[13]   Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates [J].
Goudemand, J. .
HAEMOPHILIA, 2007, 13 :47-51
[14]   Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A:: the CANAL cohort study [J].
Gouw, Samantha C. ;
van der Bom, Johanna G. ;
Auerswald, Guenter ;
Ettinghausen, Carmen Escuriola ;
Tedgard, Ulf ;
van den Berg, H. Marijke .
BLOOD, 2007, 109 (11) :4693-4697
[15]   ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? [J].
Jenkins, P. Vince ;
O'Donnell, James S. .
TRANSFUSION, 2006, 46 (10) :1836-1844
[16]   Clearance mechanisms of von Willebrand factor and factor VIII [J].
Lenting, P. J. ;
van Schooten, C. J. M. ;
Denis, C. V. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (07) :1353-1360
[17]   The impact of prophylactic treatment on children with severe haemophilia [J].
Liesner, RJ ;
Khair, K ;
Hann, IM .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) :973-978
[18]   Haemophilia prophylaxis in young patients - a long-term follow-up [J].
Lofqvist, T ;
Nilsson, IM ;
Berntorp, E ;
Pettersson, H .
JOURNAL OF INTERNAL MEDICINE, 1997, 241 (05) :395-400
[19]   25 YEARS EXPERIENCE OF PROPHYLACTIC TREATMENT IN SEVERE HEMOPHILIA-A AND HEMOPHILIA-B [J].
NILSSON, IM ;
BERNTORP, E ;
LOFQVIST, T ;
PETTERSSON, H .
JOURNAL OF INTERNAL MEDICINE, 1992, 232 (01) :25-32
[20]   Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients [J].
Powell, Jerry ;
Martinowitz, Uri ;
Windyga, Jerzy ;
Di Minno, Giovanni ;
Hellmann, Andrzej ;
Pabinger, Ingrid ;
Enriquez, Monika Maas ;
Schwartz, Lawrence ;
Ingerslev, Jorgen ;
Pabinger-Fasching, I. ;
Hermans, C. ;
Poon, M.C. ;
Ritchie, B. ;
Tinmouth, A. ;
Teitel, J. ;
Zupancic-Salek, S. ;
Ingerslev J, J. ;
Chambos H, H. ;
Schved, J.F. ;
Guillet, B ;
Oldenburg, J. ;
Klamroth, R. ;
Martinowitz, U. ;
Di Minno, Matteo Nicola Dario ;
Santagostino, E. ;
Schinco, P. ;
Musso, R. ;
Morfini, M. ;
Rocin, A. ;
Meijer, K. ;
Larosvan, B. ;
Holme, P. ;
Windyga, J. ;
Skotnicki, A. ;
Hellmann, A. ;
Zawilska, K. ;
Robak, T. ;
Soto, I. ;
Haya, S. ;
Kavakli, K. ;
Antmen, B. ;
Yesilipek, M.A. ;
Hay, C. ;
Wilde, J. ;
Rangarajan, S. ;
Bernstein, J. ;
Damon, L. ;
Gill, J. ;
Gruppo, R. ;
Cuker, A. .
THROMBOSIS AND HAEMOSTASIS, 2012, 108 (05) :913-922